These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Modulating aryl substitution: Does it play a role in the anti-leishmanial activity of a series of tetra-aryl Sb(V) fluorinated carboxylates? Artem'eva EV; Duffin RN; Munuganti S; Efremov AN; Andrews PC; Sharutina OK; Sharutin VV J Inorg Biochem; 2022 Sep; 234():111864. PubMed ID: 35636013 [TBL] [Abstract][Full Text] [Related]
16. Homo- and heteroleptic bismuth(III/V) thiolates from N-heterocyclic thiones: synthesis, structure and anti-microbial activity. Luqman A; Blair VL; Brammananth R; Crellin PK; Coppel RL; Andrews PC Chemistry; 2014 Oct; 20(44):14362-77. PubMed ID: 25224757 [TBL] [Abstract][Full Text] [Related]
17. Do bismuth complexes hold promise as antileishmanial drugs? Ong YC; Kedzierski L; Andrews PC Future Med Chem; 2018 Jul; 10(14):1721-1733. PubMed ID: 29961352 [TBL] [Abstract][Full Text] [Related]
18. Improved antileishmanial activity of Dppz through complexation with antimony(III) and bismuth(III): investigation of the role of the metal. Lizarazo-Jaimes EH; Monte-Neto RL; Reis PG; Fernandes NG; Speziali NL; Melo MN; Frézard F; Demicheli C Molecules; 2012 Oct; 17(11):12622-35. PubMed ID: 23099618 [TBL] [Abstract][Full Text] [Related]
19. Tri-aryl antimony(V) hydroximato and hydroxamato complexes: Combining lipophilic Sb(III/V) and hydroxamic acids in combating Leishmania. Soukup CRM; Duffin RN; Burke KJ; Andrews PC J Inorg Biochem; 2024 Nov; 260():112674. PubMed ID: 39088910 [TBL] [Abstract][Full Text] [Related]
20. Chemistry and Some Biological Potential of Bismuth and Antimony Dithiocarbamate Complexes. Adeyemi JO; Onwudiwe DC Molecules; 2020 Jan; 25(2):. PubMed ID: 31940910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]